Cargando…

Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models

BACKGROUND: Despite antiretroviral treatment efficacy, it does not lead to the complete eradication of HIV infection. Consequently, reactivation of the virus from latently infected cell reservoirs is a major challenge toward cure efforts. Two strategies targeting viral latency are currently under in...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Lendel Correia, Bomfim, Larissa Maciel, Dittz, Uilla Victoria Torres, Velozo, Camila de Almeida, da Cunha, Rodrigo Delvecchio, Tanuri, Amilcar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215058/
https://www.ncbi.nlm.nih.gov/pubmed/35733180
http://dx.doi.org/10.1186/s12977-022-00600-9
_version_ 1784731134858362880
author da Costa, Lendel Correia
Bomfim, Larissa Maciel
Dittz, Uilla Victoria Torres
Velozo, Camila de Almeida
da Cunha, Rodrigo Delvecchio
Tanuri, Amilcar
author_facet da Costa, Lendel Correia
Bomfim, Larissa Maciel
Dittz, Uilla Victoria Torres
Velozo, Camila de Almeida
da Cunha, Rodrigo Delvecchio
Tanuri, Amilcar
author_sort da Costa, Lendel Correia
collection PubMed
description BACKGROUND: Despite antiretroviral treatment efficacy, it does not lead to the complete eradication of HIV infection. Consequently, reactivation of the virus from latently infected cell reservoirs is a major challenge toward cure efforts. Two strategies targeting viral latency are currently under investigation: the “shock and kill” and the “block and lock.” The “Block and Lock” methodology aims to control HIV-1 latency reactivation, promoting a functional cure. We utilized the CRISPR/dCas9-KRAB platform, which was initially developed to suppress cellular genes transcription, to block drug-induced HIV-1 reactivation in latently infected T cells and myeloid cells. RESULTS: We identified a set of five sgRNAs targeting the HIV-1 proviral genome (LTR1-LTR5), having the lowest nominated off-target activity, and transduced them into the latently infected lymphoid (J-Lat 10.6) and myeloid (U1) cell lines. One of the sgRNAs (LTR5), which binds specifically in the HIV-1 LTR NFκB binding site, was able to promote robust repression of HIV-1 reactivation in latently infected T cells stimulated with Phorbol 12-Myristate 13-Acetate (PMA) and Ingenol B (IngB), both potent protein kinase C (PKC) stimulators. Reactivation with HDAC inhibitors, such as SAHA and Panobinostat, showed the same strong inhibition of reactivation. Additionally, we observed a hundred times reduction of HIV-1 RNA expression levels in the latently infected myeloid cell line, U1 induced with IngB. CONCLUSION: Taken together, our results show that the KRAB fused CRISPR/dCas9 system can robustly prevent the HIV-1 latency reactivation process, mediated by PMA or IngB and SAHA or Panobinostat, both in myeloid and lymphoid HIV-1 latently infected cells. In addition, we demonstrated that KRAB repressor protein is crucial to reactivation resistance phenotype, and we have identified some useful hotspots sequences in HIV-1 LTR for the design sgRNAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-022-00600-9.
format Online
Article
Text
id pubmed-9215058
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92150582022-06-23 Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models da Costa, Lendel Correia Bomfim, Larissa Maciel Dittz, Uilla Victoria Torres Velozo, Camila de Almeida da Cunha, Rodrigo Delvecchio Tanuri, Amilcar Retrovirology Research BACKGROUND: Despite antiretroviral treatment efficacy, it does not lead to the complete eradication of HIV infection. Consequently, reactivation of the virus from latently infected cell reservoirs is a major challenge toward cure efforts. Two strategies targeting viral latency are currently under investigation: the “shock and kill” and the “block and lock.” The “Block and Lock” methodology aims to control HIV-1 latency reactivation, promoting a functional cure. We utilized the CRISPR/dCas9-KRAB platform, which was initially developed to suppress cellular genes transcription, to block drug-induced HIV-1 reactivation in latently infected T cells and myeloid cells. RESULTS: We identified a set of five sgRNAs targeting the HIV-1 proviral genome (LTR1-LTR5), having the lowest nominated off-target activity, and transduced them into the latently infected lymphoid (J-Lat 10.6) and myeloid (U1) cell lines. One of the sgRNAs (LTR5), which binds specifically in the HIV-1 LTR NFκB binding site, was able to promote robust repression of HIV-1 reactivation in latently infected T cells stimulated with Phorbol 12-Myristate 13-Acetate (PMA) and Ingenol B (IngB), both potent protein kinase C (PKC) stimulators. Reactivation with HDAC inhibitors, such as SAHA and Panobinostat, showed the same strong inhibition of reactivation. Additionally, we observed a hundred times reduction of HIV-1 RNA expression levels in the latently infected myeloid cell line, U1 induced with IngB. CONCLUSION: Taken together, our results show that the KRAB fused CRISPR/dCas9 system can robustly prevent the HIV-1 latency reactivation process, mediated by PMA or IngB and SAHA or Panobinostat, both in myeloid and lymphoid HIV-1 latently infected cells. In addition, we demonstrated that KRAB repressor protein is crucial to reactivation resistance phenotype, and we have identified some useful hotspots sequences in HIV-1 LTR for the design sgRNAs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12977-022-00600-9. BioMed Central 2022-06-22 /pmc/articles/PMC9215058/ /pubmed/35733180 http://dx.doi.org/10.1186/s12977-022-00600-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
da Costa, Lendel Correia
Bomfim, Larissa Maciel
Dittz, Uilla Victoria Torres
Velozo, Camila de Almeida
da Cunha, Rodrigo Delvecchio
Tanuri, Amilcar
Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title_full Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title_fullStr Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title_full_unstemmed Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title_short Repression of HIV-1 reactivation mediated by CRISPR/dCas9-KRAB in lymphoid and myeloid cell models
title_sort repression of hiv-1 reactivation mediated by crispr/dcas9-krab in lymphoid and myeloid cell models
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9215058/
https://www.ncbi.nlm.nih.gov/pubmed/35733180
http://dx.doi.org/10.1186/s12977-022-00600-9
work_keys_str_mv AT dacostalendelcorreia repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels
AT bomfimlarissamaciel repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels
AT dittzuillavictoriatorres repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels
AT velozocamiladealmeida repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels
AT dacunharodrigodelvecchio repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels
AT tanuriamilcar repressionofhiv1reactivationmediatedbycrisprdcas9krabinlymphoidandmyeloidcellmodels